Sergey Brin and Emma Walmsley are not known to have a direct personal, family, employment, or business relationship. Public corporate records do, however, reveal indirect connections through the technology and healthcare industries, particularly GSK’s work with Alphabet-owned Verily and Walmsley’s position on the board of Microsoft.
Brin is the co-founder of Google and remains an influential Alphabet director and major shareholder. Walmsley is the former chief executive of pharmaceutical company GSK and remains an independent director of Microsoft as of 2026.
The combination of their names can therefore look more significant than the available evidence supports. The clearest connection is institutional rather than personal.
Sergey Brin and Emma Walmsley at a Glance
| Sergey Brin | Emma Walmsley | |
|---|---|---|
| Best known for | Co-founding Google | Former CEO of GSK |
| Main industry | Technology, internet and AI | Pharmaceuticals and healthcare |
| Current major role | Alphabet co-founder and director | Independent director of Microsoft |
| Former executive role | President of Alphabet | CEO of GSK |
| Direct relationship with the other | No verified direct relationship found | No verified direct relationship found |
| Important indirect link | Alphabet owns Verily | GSK partnered with Verily |
| Additional connection | Alphabet competes with Microsoft | Microsoft board director |
Alphabet’s 2026 proxy statement lists Brin as a Google co-founder and director who has served on the board since 1998. Microsoft filings from September 2026 identify Walmsley as a current director.
What Is the Connection Between Sergey Brin and Emma Walmsley?
There is no publicly documented evidence that Sergey Brin and Emma Walmsley are relatives, spouses, business partners, colleagues, or members of the same corporate board.
Their names instead intersect through a network of large technology and healthcare companies.
The most concrete corporate connection involves GSK and Verily Life Sciences, an Alphabet company. In August 2016, GSK announced that it was creating Galvani Bioelectronics with Verily. GSK held 55% of the venture and Verily held 45%. The companies planned to combine pharmaceutical research with electronics, data analysis and medical-device technology.
Brin was a co-founder and major owner of Alphabet, while Walmsley was already a senior GSK executive at that time. She became GSK’s chief executive the following year. That creates an indirect corporate connection, but there is no evidence that Brin and Walmsley personally negotiated or managed the Galvani partnership.
Who Is Sergey Brin?
Sergey Brin is a computer scientist and entrepreneur best known for co-founding Google with Larry Page.
Brin was born in Moscow and later studied mathematics and computer science at the University of Maryland. He completed a master’s degree in computer science at Stanford University, where he met Page. Their research project eventually developed into Google, which they established in 1998.
Brin held several senior leadership positions at Google and Alphabet. Alphabet’s corporate filings state that he served as Google’s President of Technology and later became President of Alphabet from October 2015 until December 2019.
Sergey Brin’s Current Role at Alphabet
Brin no longer serves as Alphabet’s president, but he remains closely connected to the company.
Alphabet’s 2026 proxy statement listed him as a director and co-founder. Shareholders also elected him again to the company’s board at Alphabet’s 2026 annual meeting.
His influence extends well beyond an ordinary board seat because of Alphabet’s dual-class share structure.
As of April 6, 2026, Brin beneficially owned approximately 358.94 million Class B Alphabet shares, representing about 42.9% of the Class B shares and 25.3% of Alphabet’s overall voting power. Class B shares carry ten votes each, compared with one vote for Class A shares.
Alphabet has warned investors that Brin and Larry Page together continue to possess substantial influence over shareholder votes, including director elections and major corporate transactions.
Who Is Emma Walmsley?
Dame Emma Walmsley is a British business executive best known for leading GSK, one of the world’s major pharmaceutical and vaccine companies.
Before joining GSK, Walmsley spent 17 years at L’Oréal in marketing and general-management roles across locations including Paris, London, New York and Shanghai. She joined GSK in 2010 and later became CEO of GSK Consumer Healthcare.
GSK selected Walmsley in 2016 to succeed Andrew Witty. She formally became chief executive on April 1, 2017.
Her tenure coincided with a major repositioning of GSK around vaccines and specialty medicines, as well as increased use of genetics, data and advanced technologies in pharmaceutical research.
Emma Walmsley Is No Longer GSK CEO
Walmsley’s current status is important because older profiles still describe her as GSK’s chief executive.
GSK announced on September 29, 2025 that Luke Miels would succeed her. Miels assumed full responsibilities as CEO and joined the GSK board on January 1, 2026. Walmsley stepped down as both CEO and director on December 31, 2025.
GSK’s 2025 annual report stated that her employment continued until September 30, 2026, during which she was expected to assist with the leadership transition and advise on issues involving geopolitics and new technologies.
As of October 2026, it is therefore more accurate to describe her as the former CEO of GSK.
Also Read: Charter Winfrey and Emma Walmsley
Emma Walmsley’s Microsoft Connection
One reason the Sergey Brin and Emma Walmsley search can become confusing is Walmsley’s additional role in the technology industry.
Microsoft shareholders elected Walmsley to the company’s board in December 2019. Microsoft said her global business experience and leadership in research and development would add useful expertise to the board.
She continues to serve as a Microsoft director. Microsoft’s 2026 Form 10-K lists Emma N. Walmsley among its directors, while an SEC Form 4 filed on September 11, 2026 also identifies her as a Microsoft director.
This creates another indirect connection to Brin because Microsoft and Alphabet are major competitors across areas including cloud computing, artificial intelligence, productivity software, search, advertising and consumer technology.
It should not be interpreted as evidence of a personal rivalry between Brin and Walmsley. It simply places them within companies operating in overlapping parts of the global technology economy.
The GSK and Alphabet Connection
The strongest factual link between their corporate worlds is Galvani Bioelectronics.
GSK and Verily Life Sciences announced the venture on August 1, 2016. Verily was previously known as Google Life Sciences and operates within the Alphabet group.
The venture was created to research bioelectronic medicines, an experimental approach involving small implantable devices designed to interact with electrical signals passing through nerves.
According to the original agreement:
- GSK held a 55% ownership interest.
- Verily held 45%.
- The companies proposed investment of up to £540 million over seven years, dependent on research and development milestones.
- GSK contributed expertise in disease biology and drug development.
- Verily contributed expertise in electronics, software and data analytics.
The partnership predates Walmsley’s period as GSK CEO by several months. GSK’s 2016 annual report shows that the company’s board approved the strategic combination with Verily during that year.
Walmsley subsequently became responsible for GSK as its CEO, but available corporate announcements do not establish that she and Brin personally worked together on Galvani.
Did Sergey Brin and Emma Walmsley Work Together?
There is no reliable public record showing that Sergey Brin and Emma Walmsley worked together directly.
The GSK-Verily partnership involved companies associated with both executives, but corporate partnerships do not automatically mean senior leaders personally collaborated.
The 2016 announcement specifically identified GSK executive Moncef Slaoui and Verily executives including Chief Technology Officer Brian Otis and CEO Andrew Conrad in connection with establishing Galvani Bioelectronics. Brin and Walmsley were not presented as the leaders of the transaction.
This distinction matters because articles built from company associations can easily create a misleading impression of a direct relationship.
Are Sergey Brin and Emma Walmsley Related?
There is no credible evidence that Sergey Brin and Emma Walmsley are related by family.
Their established biographies have entirely separate backgrounds. Brin came from an academic and technology background and built Google after studying at Stanford. Walmsley developed her career in consumer goods and pharmaceuticals after studying Classics and Modern Languages at Oxford University.
No authoritative biography, company filing or reputable public record reviewed for this article identifies a family relationship between them.
Do They Share Any Company Boards?
No current public filing reviewed shows Sergey Brin and Emma Walmsley serving together on the same board.
Brin serves on Alphabet’s board.
Walmsley serves on Microsoft’s board and retired from GSK’s board at the end of 2025.
This actually places their current board positions at two separate technology companies that compete in several important markets.
How Their Careers Differ
Brin’s career has largely centered on building and financing technology.
His work grew from academic research into search engines and data mining to the creation of Google, followed by Alphabet’s expansion into areas such as artificial intelligence, autonomous technologies, life sciences and advanced computing.
Walmsley’s career developed through consumer products before moving increasingly toward pharmaceuticals, vaccines and biotechnology.
As GSK CEO, she led a company focused on medicines and vaccines rather than consumer technology. Her Microsoft board position nevertheless gives her a direct governance role within one of the world’s largest technology companies.
The overlap between them is therefore best described as technology, healthcare innovation and corporate governance, not a direct partnership.
Financial and Ownership Differences
Their financial relationships with their respective companies are also very different.
Brin is one of Alphabet’s founders and remains one of its largest voting shareholders. Alphabet’s April 2026 proxy attributed 25.3% of total voting power to him individually.
Walmsley was a professional executive rather than the founder or controlling shareholder of GSK. GSK reported total remuneration of approximately £15.68 million for 2025, including salary, benefits, bonus and long-term incentive awards that vested based on performance.
These figures should not be confused with personal net worth. Corporate compensation, share ownership and estimated net worth measure different things, and publicly circulating wealth estimates can fluctuate significantly.
Why Are Sergey Brin and Emma Walmsley Mentioned Together?
The combination most likely reflects searches attempting to understand whether two prominent global business figures have a relationship.
There are several genuine reasons their professional worlds can appear connected:
- Brin co-founded Google and remains an influential Alphabet director.
- Alphabet owns Verily Life Sciences.
- GSK partnered with Verily to establish Galvani Bioelectronics.
- Walmsley subsequently led GSK from 2017 through the end of 2025.
- Walmsley has served on Microsoft’s board since 2019.
- Microsoft and Alphabet compete heavily in modern technology and artificial intelligence.
None of those facts establishes a personal relationship between Brin and Walmsley.
The evidence instead shows several degrees of institutional connection between the companies around them.
FAQ
Are Sergey Brin and Emma Walmsley connected?
Only indirectly based on publicly available evidence. GSK, the company formerly led by Walmsley, partnered with Alphabet subsidiary Verily, while Brin is an Alphabet co-founder, director and major shareholder. There is no verified direct relationship between Brin and Walmsley.
Did Sergey Brin and Emma Walmsley work together?
There is no reliable public evidence that they personally worked together. Their companies have occupied overlapping technology and healthcare networks, particularly through the GSK-Verily Galvani Bioelectronics partnership.
Are Sergey Brin and Emma Walmsley related?
No credible source reviewed identifies them as relatives. Their documented personal and professional backgrounds are separate.
Does Emma Walmsley work for Google or Alphabet?
No. Walmsley is the former CEO of GSK and serves as an independent director of Microsoft. Microsoft and Alphabet are separate companies and major competitors.
Is Emma Walmsley still CEO of GSK?
No. She stepped down as CEO and a GSK director on December 31, 2025. Luke Miels became GSK’s CEO on January 1, 2026. Her transitional employment arrangements with GSK continued through September 30, 2026.
Is Sergey Brin still involved with Google?
Yes, through Alphabet. Brin remains an Alphabet co-founder, director and major shareholder, although he has not served as Alphabet’s president since December 2019.
Also Read: John Malone and Emma Walmsley
